Twin City Private Wealth LLC Acquires 2,096 Shares of Becton, Dickinson and Company $BDX

Twin City Private Wealth LLC grew its holdings in Becton, Dickinson and Company (NYSE:BDX) by 18.2% in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 13,581 shares of the medical instruments supplier’s stock after acquiring an additional 2,096 shares during the period. Becton, Dickinson and Company accounts for approximately 1.9% of Twin City Private Wealth LLC’s holdings, making the stock its 14th largest position. Twin City Private Wealth LLC’s holdings in Becton, Dickinson and Company were worth $2,339,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in BDX. Brighton Jones LLC grew its position in Becton, Dickinson and Company by 98.2% in the fourth quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier’s stock worth $401,000 after acquiring an additional 877 shares in the last quarter. Private Trust Co. NA grew its position in Becton, Dickinson and Company by 3.9% in the first quarter. Private Trust Co. NA now owns 3,866 shares of the medical instruments supplier’s stock worth $886,000 after acquiring an additional 145 shares in the last quarter. D.A. Davidson & CO. grew its position in Becton, Dickinson and Company by 37.6% in the first quarter. D.A. Davidson & CO. now owns 49,966 shares of the medical instruments supplier’s stock worth $11,445,000 after acquiring an additional 13,648 shares in the last quarter. Calamos Advisors LLC grew its position in Becton, Dickinson and Company by 1.1% in the first quarter. Calamos Advisors LLC now owns 61,868 shares of the medical instruments supplier’s stock worth $14,171,000 after acquiring an additional 688 shares in the last quarter. Finally, 44 Wealth Management LLC bought a new stake in Becton, Dickinson and Company in the first quarter worth approximately $414,000. 86.97% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several analysts have commented on BDX shares. Royal Bank Of Canada reissued a “sector perform” rating and issued a $211.00 target price on shares of Becton, Dickinson and Company in a research report on Thursday, October 16th. Wall Street Zen upgraded shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research note on Saturday, August 9th. Piper Sandler reiterated a “neutral” rating and issued a $200.00 target price (up previously from $185.00) on shares of Becton, Dickinson and Company in a report on Friday, August 8th. Wells Fargo & Company boosted their target price on shares of Becton, Dickinson and Company from $172.00 to $184.00 and gave the stock an “equal weight” rating in a research report on Friday, August 8th. Finally, Morgan Stanley boosted their target price on shares of Becton, Dickinson and Company from $196.00 to $197.00 and gave the stock an “overweight” rating in a research report on Monday, August 11th. Three research analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $205.40.

Insider Activity at Becton, Dickinson and Company

In other news, Director Claire Fraser sold 917 shares of the firm’s stock in a transaction dated Wednesday, September 10th. The shares were sold at an average price of $187.50, for a total transaction of $171,937.50. Following the completion of the transaction, the director directly owned 22,226 shares of the company’s stock, valued at approximately $4,167,375. This trade represents a 3.96% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Over the last ninety days, insiders have sold 1,895 shares of company stock worth $358,995. 0.36% of the stock is currently owned by company insiders.

Becton, Dickinson and Company Price Performance

Shares of Becton, Dickinson and Company stock opened at $178.77 on Friday. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.10 and a quick ratio of 0.62. Becton, Dickinson and Company has a fifty-two week low of $163.33 and a fifty-two week high of $251.99. The firm has a fifty day moving average price of $188.38 and a two-hundred day moving average price of $183.17. The company has a market cap of $51.24 billion, a PE ratio of 32.15, a price-to-earnings-growth ratio of 1.42 and a beta of 0.25.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings results on Thursday, April 14th. The medical instruments supplier reported $4.10 earnings per share for the quarter. Becton, Dickinson and Company had a net margin of 7.51% and a return on equity of 16.23%. The firm had revenue of $5.32 billion during the quarter. Analysts expect that Becton, Dickinson and Company will post 14.43 EPS for the current year.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.